American Century Companies Inc. Has $3.37 Million Stake in Agios Pharmaceuticals, Inc. $AGIO

Key Points

• American Century Companies Inc. increased its stake in Agios Pharmaceuticals by 9.6%, owning 114,947 shares worth approximately $3.37 million as of the latest SEC filing.
• Agios Pharmaceuticals received mixed analyst ratings, with target prices being lowered by Scotiabank and Bank of America, while maintaining a consensus rating of "Moderate Buy" with a target price of $56.33.
• Insider trading activity includes CEO Brian Goff selling 11,085 shares at an average price of $36.67, resulting in a decrease of 8.23% of his holdings.

American Century Companies Inc. raised its holdings in Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Free Report) by 9.6% during the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 114,947 shares of the biopharmaceutical company's stock after purchasing an additional 10,110 shares during the quarter. American Century Companies Inc. owned 0.20% of Agios Pharmaceuticals worth $3,368,000 as of its most recent SEC filing.

A number of other large investors have also recently modified their holdings of the business. PNC Financial Services Group Inc. boosted its holdings in shares of Agios Pharmaceuticals by 16.2% in the 1st quarter. PNC Financial Services Group Inc. now owns 3,582 shares of the biopharmaceutical company's stock valued at $105,000 after purchasing an additional 499 shares in the last quarter. Gallagher Fiduciary Advisors LLC lifted its stake in shares of Agios Pharmaceuticals by 7.6% in the 4th quarter. Gallagher Fiduciary Advisors LLC now owns 11,110 shares of the biopharmaceutical company's stock valued at $365,000 after acquiring an additional 788 shares during the last quarter. Envestnet Asset Management Inc. lifted its stake in shares of Agios Pharmaceuticals by 3.3% in the 4th quarter. Envestnet Asset Management Inc. now owns 24,805 shares of the biopharmaceutical company's stock valued at $815,000 after acquiring an additional 795 shares during the last quarter. CWM LLC lifted its stake in shares of Agios Pharmaceuticals by 150.2% in the 1st quarter. CWM LLC now owns 1,659 shares of the biopharmaceutical company's stock valued at $49,000 after acquiring an additional 996 shares during the last quarter. Finally, GF Fund Management CO. LTD. bought a new position in shares of Agios Pharmaceuticals in the 4th quarter valued at $39,000.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on AGIO. Bank of America dropped their price target on Agios Pharmaceuticals from $52.00 to $51.00 and set a "buy" rating for the company in a research note on Tuesday, July 22nd. Wall Street Zen cut Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a research note on Monday, May 19th. Scotiabank dropped their price target on Agios Pharmaceuticals from $71.00 to $65.00 and set a "sector outperform" rating for the company in a research note on Monday, July 28th. Finally, HC Wainwright reiterated a "buy" rating and issued a $56.00 price target on shares of Agios Pharmaceuticals in a research note on Thursday. Six research analysts have rated the stock with a Buy rating and two have assigned a Hold rating to the company's stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average target price of $56.00.

Agios Pharmaceuticals Stock Performance

Shares of AGIO stock traded down $4.45 during mid-day trading on Thursday, hitting $36.16. The company's stock had a trading volume of 2,140,287 shares, compared to its average volume of 711,344. The company's fifty day simple moving average is $37.48 and its 200-day simple moving average is $33.17. Agios Pharmaceuticals, Inc. has a 52 week low of $23.42 and a 52 week high of $62.58. The company has a market cap of $2.10 billion, a PE ratio of 3.29 and a beta of 0.87.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last posted its quarterly earnings data on Thursday, July 31st. The biopharmaceutical company reported ($1.93) earnings per share for the quarter, missing the consensus estimate of ($1.74) by ($0.19). Agios Pharmaceuticals had a negative return on equity of 3.49% and a net margin of 1,590.42%.The business had revenue of $12.50 million during the quarter, compared to the consensus estimate of $9.46 million. On average, equities analysts anticipate that Agios Pharmaceuticals, Inc. will post -6.85 earnings per share for the current year.

Insider Buying and Selling

In other news, insider Sarah Gheuens sold 11,914 shares of the firm's stock in a transaction dated Wednesday, July 9th. The stock was sold at an average price of $37.99, for a total value of $452,612.86. Following the completion of the sale, the insider directly owned 61,271 shares in the company, valued at $2,327,685.29. This trade represents a 16.28% decrease in their position. The sale was disclosed in a filing with the SEC, which is available at this link. Also, Director David Scadden sold 1,400 shares of the firm's stock in a transaction dated Thursday, July 10th. The shares were sold at an average price of $40.00, for a total value of $56,000.00. Following the completion of the sale, the director owned 17,603 shares of the company's stock, valued at approximately $704,120. This represents a 7.37% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 57,448 shares of company stock worth $2,026,141 over the last 90 days. 4.93% of the stock is owned by company insiders.

Agios Pharmaceuticals Profile

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.